Standardized Annual Returns (thru April 30)
  
    | Year-to-date | 1 year | 5 years | 10 years | Since Incep. | 
  
    | -99.6% | -99.6% | -64.2% | -40.0% | -37.3% | 
 
       
          Market Correlations
          
            | versus... | Beta | R-squared | 
          
            | S&P500 | 0.56 | 39% | 
          
            | MSCI EAFE | 0.42 | 23% | 
          
            | MSCI Emg. Mkts. | 0.24 | 7% | 
        
	
   
      
      Technical Indicators
      
        | Recent close | $51.03 | 
      
        | 30d moving avg. | $44.56 | 
      
        | Annualized volatility | 15.0% | 
      
        | Short interest (ETF) | 0.0% | 
      
        | Short interest (Underlying) | 5.0% | 
  
      
        | Relative strength (RSI) | 8 | 
      
   
      
      Liquidity measures
      
        | Avg. volume (thou.) | 9,575 | 
      
        | Turnover | 1,473.1% | 
      
        | Bid/Ask (% of price) | 0.14% | 
      
        | ADV underlying (mns) | $13,549 | 
      
      
 
    
 
    
   
  
			
				|  | There were no matches found with other funds under coverage. | 
			
  
  
      Content on this tab for subscribers only**
      
      
        
          
            |  | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | 
          
            | Sales per share | ** | ** | ** | ** | ** | ** | ** | 
          
            | Earnings per share | ** | ** | ** | ** | ** | ** | ** | 
          
            | Dividends per share  | ** | ** | ** | ** | ** | ** | ** | 
          
            | Book value per share | ** | ** | ** | ** | ** | ** | ** | 
        
   
    
        
          
            | Sales per share growth |  | **% | **% | **% | **% | **% | **% | 
          
            | EPS growth |  | **% | **% | **% | **% | **% | **% | 
          
       
        
          
            | Sales per share growth |  | **% | **% | **% | **% | **% | **% | 
          
            | EPS growth |  | **% | **% | **% | **% | **% | **% | 
          
         
      
      
      
  
    
      | Long term EPS growth est. | **% |  | Debt-to-equity | **x | 
    
      | Asset turnover | **% |  | Assets-to-equity | **x | 
  
   
  
   
  
    
  
	
    Revision activity*
    	
      	 |  | 
     	
         | *Six months ago = 100 | 
	
	
   
  
    
	
	
    Compound annual growth rates
        
          |  | 
	
	
        
    
  
      Content on this tab for subscribers only
	
    
      
        |  | 2024 | 2025E | 2026E | 
      
        | Price-to-sales | ** | ** | ** | 
      
        | Price-to-earnings | ** | ** | ** | 
      
        | Price-to-cash flow | ** | ** | ** | 
      
        | Price-to-growth | ** | ** | ** | 
      
        | Price-to-book value | ** | ** | ** | 
      
        | Yield | ** | ** | ** | 
      
 
     
      
		   
     
    
      	
      		| AVOID | 
        
        	| Not worthwhile for most investors.  A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant. | 
     
	
    	| 
		
  
            
            | Calculation of ALTAR Score™ | 
              | Avg. Return on Equity | 13.5 | % |  
              | Divided by: Fwd. P/BV | 0.0 | x |  
              | Less: Expense ratio | 42 | bp |  
              | Equals: ALTAR Score | 0.0 | % |  
              |  |  
              |  More information on ALTAR Score™ |  |  |  | 
  
	
    
    	
			| 
   				
      				| COMPOSITE RATING
 | 1.64 | CATEGORY AVERAGE
 | 1.59 |  
   					|  |  
						| The composite rating is a weighted average of analysts' 
						consensus recommendations for individual ETF constituents, based on the following scale: 
 BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3.
 
 Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be
						more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.
 |  |  |  |